Beta Drugs posts 29% H1 growth and sees further margin gains

Management guided margin improvementOrder pipeline disclosedInvestor Communications View source PDF Explain this filing

BETA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-3.5%Reaction day

₹1957.90

prior close

₹1976.80

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.7%-4.1% vs market

Pharmaceuticals peers, median of 171sector+0.4%-3.8% vs sector

On the reaction day the stock moved 4.1 pts less than Nifty Microcap 250 and 3.8 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.7

10m

-0.1

15m

-0.5

30m

+0.2

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-3.5+0.7-4.1+0.4-3.8

Next day

-8.1-1.9-6.2-0.6-7.5

-8.6-0.4-8.1-0.4-8.1

-12.6-0.2-12.4-0.1-12.5

-9.0+2.0-11.0+0.7-9.8

-5.7+3.1-8.8+1.8-7.5

—————

15d

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 171Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

For H1 FY27, revenue grew 29.2% and profit after tax rose to INR 34 crore from INR 24 crore, up about 45%. Reported EBITDA margin was 23.18% versus 23.08%, or 22% without other income. Management expects 20-25% growth and 23-24% margins over 3-5 years. Trade-margin price caps should have negligible impact. FY27 targets are INR 150 crore own brands, INR 90-100 crore exports and INR 180-190 crore CMO. Capex and NDDS revenue were not quantified.

Likely market impact

Positive: profit growth and margin expansion support earnings, but tender timing, drug ingredient supply and limited capex disclosure are risks.